<DOC>
	<DOCNO>NCT02072096</DOCNO>
	<brief_summary>The main purpose study compare benefit risk associate use 2 treatment strategy low blood sugar participant age 65 old T2DM . One strategy base use oral injectable medication reduce blood sugar ( glucose ) high . The strategy base non-glucose dependent agent . The trial last 72 week participant .</brief_summary>
	<brief_title>A Comparison Two Treatment Strategies Older Participants With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Have T2DM base history clinical impression consistent World Health Organization ( WHO ) Classification Diabetes Have Clinical Frailty Scale ( CFS ) score 4 Total Illness Burden Index ( TIBI ) score 5 assessed screen Have A1c &gt; 7.3 % &lt; 10.9 % study entry achieve desired glycemic control evidence A1c measurement least 0.4 % high individualized treatment target set screening . Have treat least 3 month prior study entry follow treatment option : Diet/exercise ( know contraindication metformin treatment ) Any dose sulfonylurea Effective maximallytolerated dos metformin , dipeptidylpeptidase4 ( DPP4 ) inhibitor , thiazolidinedione , acarbose used monotherapy dual combination . The following dos consider effective : least 1500 mg metformin per day At least 30 mg pioglitazone per day At least 4 mg rosiglitazone per day At least 75 mg acarbose per day Any market dose DPP4 inhibitor Are currently enrol clinical trial involve investigational product nonapproved use drug device ( investigational product use study ) , concurrently enrol type medical research judge scientifically medically compatible study Have participate , within last 60 day clinical trial involve investigational product investigational product use study . If previous investigational product long halflife , 3 month 5 halflives ( whichever longer ) pass Have previously complete withdrawn study . This exclusion criterion apply participant rescreened prior randomization At study entry , contraindication sulfonylurea , insulin , GLP1 RA Have history pancreatitis , personal family history medullary thyroid carcinoma , Multiple Endocrine Neoplasia syndrome type 2 Have take injectable glucoselowering agent , miglitol , meglitinide , Sodium/Glucose cotransporter2 inhibitor , antihyperglycemia treatment list fourth inclusion criterion 10 day within 3 month prior study entry In opinion investigator individualize A1c target set 8 % high Have body mass index ( BMI ) great 45 kg/m^2 Have 1 episode severe hypoglycemia within 24 week prior study Have cardiac disease functional status Class III IV accord New York Heart Association Cardiac Disease Classification Have estimate glomerular filtration rate ( eGFR ) &lt; 30 milliliter/minute/1.73 m^2 ( mL/min/1.73 m^2 ) advance renal disease include history renal transplantation currently receive renal dialysis Have obvious clinical sign symptom laboratory evidence liver disease ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 2.5 time upper limit reference range ) Receive current therapy malignancy , basalcell squamouscell skin cancer Received systemic glucocorticoid within 3 month prior entry 14 consecutive day Have condition precludes participant follow completing study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>